Trifluridine and tipiracil tablets, typically available in the strength of 20mg trifluridine and 8.19mg tipiracil, are used in the treatment of certain types of advanced or metastatic cancers. Here's an overview of its use:
1. Colorectal Cancer Trifluridine and tipiracil tablets are approved for the treatment of metastatic colorectal cancer (CRC) that has progressed after standard chemotherapy and other treatments. It is specifically indicated for patients who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.
2. Gastric or Gastroesophageal Junction (GEJ) Cancer Trifluridine and tipiracil tablets may also be used in the treatment of advanced gastric (stomach) or gastroesophageal junction (GEJ) cancer in patients who have previously received at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, and either a taxane or irinotecan.
Trifluridine is a nucleoside analog that interferes with the synthesis of DNA, which is necessary for cancer cell replication. Tipiracil is a thymidine phosphorylase inhibitor that helps maintain effective trifluridine levels in the bloodstream by inhibiting its degradation. The combination of trifluridine and tipiracil allows for improved delivery and retention of trifluridine within cancer cells, enhancing its anti-cancer effects.
These tablets are typically taken orally as directed by a healthcare professional. The dosage and treatment regimen may vary depending on factors such as the type and stage of cancer, overall health, and individual response to treatment. Common side effects may include fatigue, nausea, vomiting, diarrhea, decreased appetite, and low blood cell counts.
It's important for patients to be monitored closely by their healthcare provider while taking trifluridine and tipiracil tablets to manage any side effects and ensure the treatment remains effective. As with any cancer treatment, it's crucial to discuss the potential benefits and risks with a healthcare professional to make informed decisions about treatment options.